Although GLP-1 shows therapeutic effects in metabolic diseases, the half-life of GLP-1 is very short and it is quickly cleaved into the inactive truncated form by dipeptidyl peptidase-4 (DPP-4) within a few minutes (Deacon et al., 1995; Marathe et al., 2013). This evidence concerns the gene DPP4 and metabolic disease.